Cullinan Oncology, in partnership with Taiho Pharmaceutical (TADAWUL:2070), a subsidiary of Otsuka Holdings Co (OTC:OTSKY). (4578-JP; not rated), is planning to engage in discussions with the FDA ...

Cullinan Oncology LLC (CGEM) stock has reached a new 52-week low, trading at $9.48 USD, signaling a period of significant bearish momentum for the biotechnology company.

BTIG has reaffirmed its Buy rating and a $30.00 price target for Cullinan Oncology Inc. (NASDAQ: CGEM). The company has recently... ByInvesting.com • Sep 18, 2024 Cullinan Oncology maintains Buy ...

Cullinan Therapeutics ... The company is committed to advancing its pipeline in immunology and oncology, with multiple ongoing trials and an emphasis on impactful catalysts for 2025.

Oncology The Company continues enrollment of disease-specific expansion cohorts of its Phase 1 study. Cullinan remains on track to report initial data for endometrial and cervical cancers in the ...

Cullinan Oncology, Inc. is a biopharmaceutical company engaged in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on September 15, 2016 and is ...

Cullinan Oncology’s strategic approach to research and development, focusing on modality-agnostic target oncology, positions the company to thrive.

ByInvesting.com • May 23, 2024 Cullinan Therapeutics Files for 14.42M Share Offering by Selling Stockholders Cullinan Therapeutics (CGEM) has filed for up to 14,421,070 share offering by selling ...

Zipalertinib (EGFR ex20ins inhibitor), collaboration with Taiho Oncology: EGFR ex20ins NSCLC In January 2025, Cullinan announced that the pivotal Phase 2b portion of REZILIENT1 met the primary ...